Daily intraperitoneal administration of cytarabine in a patient with peritoneal mesothelioma.
A 58 year old male with advanced peritoneal malignant mesothelioma was treated with the daily (5 days/week) intraperitoneal administration of cytarabine in a large treatment volume (1-2 liters) for 7 weeks. While a clinical benefit was not observed, there was no systemic toxicity (except for mild emesis) during or following the intraperitoneal treatment program. Long-term exposure of slow growing solid tumors in the peritoneal cavity to a cell-cycle phase-specific agent with limited systemic exposure and toxicity is an innovative and potentially important means of rationally utilizing this class of anti-neoplastic drugs.
D002945:Cisplatin / Q000627:therapeutic use; D003561:Cytarabine / Q000008:administration & dosage* / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy*; D008875:Middle Aged; D010537:Peritoneum
D003561:Cytarabine; D004317:Doxorubicin; D002945:Cisplatin